



The 2nd Annual London Genetics Pharmacogenetics Conference

Pharmacogenetics: Why, How and When? Challenges, Opportunities and How to Harness the Value

9th–10th November 2010

Cumberland Lodge,
Windsor, UK

Preliminary Programme

Topics

- How genetics is contributing to effective new medicines
- Latest pharmacogenetics guidance from the EMA and FDA
- How the industry is using pharmacogenetics
- How to design fit-for-purpose pharmacogenetics studies
- The changing payer environment and cost-effectiveness
- Latest genetics research from London Genetics' academic partners

Confirmed Speakers

- Krishna Prasad – EMA Pharmacogenetic Working Party, Medicines and Healthcare products Regulatory Agency
- John Whittaker – GlaxoSmithKline, Director, Statistical Genetics, GlaxoSmithKline
- Dominic Smethurst – Amgen, Medical Director, Amgen (Europe) GmbH
- Clive Bowman – School of Biological Sciences, University of Reading; School of Mathematics, University of Leeds
- Felix Frueh – Vice President, R&D Personalized Medicine, Medco Health Solutions, Inc.
- Ebenezer Tetteh – Health Economist, UK Office of Health Economics
- Arthur L. Holden – Chairman and CEO, International Serious Adverse Events Consortium
- Stephen Little – VP Personalized Healthcare, Qiagen

For more information or to register please visit our website www.londongenetics.com.
Alternatively you can contact croberts@londongenetics.com or call **+44 (0)20 7594 1838**.

